Clinical trial · Observational
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly functional patients, they do not present co morbidities and could benefit from oncology therapies. Treatment planning must consider several health indices that are useful when it comes to detecting geriatric problems that could affect the patient's treatment experience. The complete comprehensive geriatric evaluation stands out as cornerstone among other validated tools that do not work as isolated instruments; however, its length and complexity may hinder its routine use in clinical practice for decision making. The purpose of this study is to validate a comprehensive health status assessment scale in elderly patients (≥65 years) with hematological malignancies that, while integrating the essential dimensions of geriatric assessment and, with the same precision as the currently available valid tools, is shorter and easier to apply, so it can be incorporated into the daily practice and that aids in clinical decision making objectively. If so, this information would help identify patients that could benefit from a specific oncology treatment, thus contributing to developing a targeted intervention plan and to optimizing the cancer results in this patient population.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia Myeloid Acute | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Leuklemia, Lymphocytic, Chronic | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Geriatric Assessment of Health Status Scale administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Multiple Myeloma (MM)
- description
- Patients with Myltiple Myeloma, symptomatic or asymptomatic
- interventionNames
- Other: Geriatric Assessment of Health Status Scale administration
- label
- Myelodysplastic Syndromes or Acute Myeloid Leukemia
- description
- Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
- interventionNames
- Other: Geriatric Assessment of Health Status Scale administration
- label
- Chronic Lymphocytic Leukemia (CLL)
- description
- Patients with Chronic Lymphocytic Leukemia
- interventionNames
- Other: Geriatric Assessment of Health Status Scale administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Patients ≥ 65 years old. Treatment-naïve patients Newly diagnosed patients who belong to one of the 3 following groups: Patients with MDS (any risk grade as per IPSS) or AML Patients with multiple myeloma (symptomatic or not) or Patients with chronic lymphocytic leukemia (including A status) Patients who have granted their informed consent. Exclusion Criteria: Not fulfilling selection criteria
References
Publications (0)
Data not yet available